Pharmaceutical US pharma giant Merck & Co has announced that the European Commission (EC) has approved Winrevair (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with World Health Organization (WHO) functional class (FC) II to III, to improve exercise capacity. 27 August 2024